Vicente Bertomeu-González, Francisco Fernández-Avilés, Juan Manuel Nogales-Asensio, Sergio Raposeiras-Roubín, José María García Acuña, David Martí Sánchez, Albert Ariza Solé, Juan Carlos Gómez Polo, Aida Ribera, Juan Sanchis, María Asunción Esteve-Pastor, Josep Ramon Marsal, Ana Viana Tejedor, Juan M. Ruiz-Nodar, Francisco Marín Ortuño, Antonio Chacón Piñero, Manuel Almendro-Delia, Damaris Carballeira Puentes, Manuel Anguita, Iñigo Lozano, José Luis Ferreiro, Emad Abu-Assi, Rosa Agra Bermejo, Pedro L. Sánchez, Melisa Santás-Álvarez, Amparo Valls-Serral, Alberto Cordero, and Angel Cequier
Introduction and objectives Despite evidence of a reduction in the incidence and mortality of acute coronary syndrome (ACS), some studies have highlighted differences in outcomes between men and women. We aimed to explore sex differences in the management and treatment of patients with ACS in Spain. Methods This ecological cross-sectional study combined ACS data from 10 Spanish registries (54 centres). Meta-regression analysis was performed using aggregated data of baseline characteristics, interventional procedures, treatments, and events that occurred during hospitalization and one-year follow-up. Results Aggregated data from 34 605 patients (75.1% men) was included. ST-segment elevation myocardial infarction was the most frequent diagnosis (58.9%) and almost 80% of patients were Killip Class I. Compared to men, women were older (mean age: 71.0 vs 63.3 years) and presented higher rates of hypertension (68.1% vs 51.7%) and diabetes (37.7% vs 26.5%). Women were also less likely to undergo percutaneous coronary interventions, revascularization surgery, and to receive drug-eluting stents during hospitalization. Regarding to antiplatelet therapy, even though indicated, 23.1% of women were not treated with P2Y12 inhibitors (vs 14.2% of men; P 60%). Significantly higher in-hospital (5.4% vs 3.7%) and 1-year (8.2% vs 4.9%) mortality was observed among women compared to men, which was mainly attributed to cardiovascular causes. Conclusions Despite older age and unfavourable risk profile, female ACS patients seem to be suboptimally treated with P2Y12 inhibitors. To reduce mortality associated with ACS, improved prevention and optimized therapeutic approaches are needed.